Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Plasma cell 1

Conditions

Ras-mutated Metastatic Colorectal Cancer 1Multiple Myeloma 1Anal Cancer Metastatic 1

Interventions

Specimen Handling 427Magnetic Resonance Spectroscopy 338pembrolizumab 262Biopsy 230Carboplatin 216Cisplatin 180Cyclophosphamide 174Paclitaxel 148Nivolumab 136Gemcitabine 130Radiotherapy 125Dexamethasone 105Bevacizumab 103Radiation 97fludarabine 95Fluorouracil 93Doxorubicin 90Pemetrexed 88Docetaxel 85Rituximab 83durvalumab 82venetoclax 81Oxaliplatin 81Leucovorin 76atezolizumab 70Prednisone 66Lenalidomide 66Capecitabine 66Etoposide 64Vincristine 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
reolysin × 30 days × Clear all
NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting
122 enrolled
Gastrointestinal

Anal Cancer Metastatic

NCT05514990 2026-05-13

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

University of Southern California

Phase 1/2 Active not recruiting
10 enrolled
Plasma cell

Multiple Myeloma

NCT07446322 2026-05-05

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

Oncolytics Biotech

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Ras-mutated Metastatic Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡